A novel recombinant adenovirus type-5 vector-based Ebola vaccine based on the 2014 Zaire Guinea Ebola strain, which is responsible for the current Ebola epidemic, elicited a robust immune response in recipients, according to the first phase 1 trial of the vaccine. (Zhu F-C et al. Lancet. doi:10.1016/S0140-6736(15)60553-0 [published online March 24, 2015]).
The trial, conducted in China, randomly assigned 120 healthy Chinese adults to receive placebo or a low dose or high dose of the vaccine. Twenty-eight days after vaccination, 38 of 40 participants in the low-dose group and all 40 of those in the high-dose group had a positive immune response to the vaccine, with the magnitude of the immune response being dose-dependent. No specific immune response was recorded in the placebo group, and no serious adverse events were reported in any group.
Slomski A. High-Dose Novel Ebola Vaccine Immunogenic and Safe. JAMA. 2015;313(20):2015. doi:10.1001/jama.2015.4358